Chemistry: molecular biology and microbiology – Virus or bacteriophage – except for viral vector or... – Recovery or purification
Reexamination Certificate
2005-03-03
2008-11-04
Campell, Bruce (Department: 1648)
Chemistry: molecular biology and microbiology
Virus or bacteriophage, except for viral vector or...
Recovery or purification
C424S232100
Reexamination Certificate
active
07445924
ABSTRACT:
The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus and characterized by the loss of its capability to reproductively replicate in human cell lines. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised, receiving antiviral therapy, or have a pre-existing immunity to the vaccine virus. In addition, a method is provided for the administration of a therapeutically effective amount of the virus, or its recombinants, in a vaccinia virus prime/vaccinia virus boost innoculation regimen. The present invention relates to a method of virus amplification in primary cells which are cultivated in a serum free medium. Viruses produced by this method are advantageously free of any infectious agents comprised in animal sera.
REFERENCES:
patent: 4072565 (1978-02-01), Weiss et al.
patent: 5155020 (1992-10-01), Paoletti
patent: 5185146 (1993-02-01), Altenburger et al.
patent: 5403582 (1995-04-01), Nazerian et al.
patent: 5405772 (1995-04-01), Ponting
patent: 5494807 (1996-02-01), Paoletti et al.
patent: 5753489 (1998-05-01), Kistner et al.
patent: 5756341 (1998-05-01), Kistner et al.
patent: 5789245 (1998-08-01), Dubensky, Jr. et al.
patent: 6761893 (2004-07-01), Chaplin et al.
patent: 6913752 (2005-07-01), Chaplin et al.
patent: 7056723 (2006-06-01), Heller et al.
patent: 7097842 (2006-08-01), Suter et al.
patent: 2002/0022268 (2002-02-01), Xu et al.
patent: 2003/0013190 (2003-01-01), Mayr
patent: 2003/0228330 (2003-12-01), Falkner et al.
patent: 2005/0214324 (2005-09-01), Rathe et al.
patent: 2005/0271688 (2005-12-01), Chaplin et al.
patent: 2006/0093620 (2006-05-01), Falkner et al.
patent: 2006/0127984 (2006-06-01), Ackermann et al.
patent: 2006/0280758 (2006-12-01), Chaplin et al.
patent: 2370573 (2002-07-01), None
patent: WO 92/05246 (1992-04-01), None
patent: WO 97/02355 (1997-01-01), None
patent: WO9702355 (1997-02-01), None
patent: WO 97/31119 (1997-08-01), None
patent: WO 98/04680 (1998-02-01), None
patent: WO98/15614 (1998-04-01), None
patent: WO 98/56919 (1998-12-01), None
patent: WO 99/07869 (1999-02-01), None
patent: WO 00 28016 (2000-05-01), None
patent: WO 00/29428 (2000-05-01), None
patent: WO 01 68820 (2001-09-01), None
patent: WO 01/89559 (2001-11-01), None
patent: WO 02/24224 (2002-03-01), None
patent: WO02/42480 (2002-05-01), None
Asher D.M., Bovine Sera Used in the Manufacture of Biologicals: Currents Concerns and Policies of the U.S. Food and Drug Administration Regarding the Transmissible Spongiform Encephalopathies, 1999, Developments in Biological Standardization, vol.99, pp. 41-44.
Kozak et al., Transmissible Spongiform Encephalopathies (TSE): Minimizing the Risk of Transmission of Biological/Biopharmaceutical Products: an Industry Perspective, 1996, Developments in Biological Standardization, vol. 88, pp. 257-264.
In the matter of: Certain Modified Vaccinia Ankara (“MVA”) Viruses and Vaccines and Pharmaceutical Compositions Based Thereon, Investigation No. 337-TA-550, Commission Opinion On behalf of the Office of the Secretary, Document ID: 270867, United States International Trade Commission, Washington, D.C., Mar. 6, 2007.
Grob et al., Role of the Individual Interferon Systems and Specific Immunity in Mice in Controlling Systemic Dissemination of Attenuated Pseudorabies Virus Infection, 1999, Journal of Virology, vol. 73, No. 6, pp. 4748-4754.
Pietrzkowski, et al. “Dextran T-500 improves survival and spreading of chick embryo cells in serum-free medium” Folia Histochemica Et Cytobiologica, vol. 26, No. 3, 1988, p. 123-132.
Stittelaar, et al., Vaccine 19: 3700-3709, 2001.
Sutter and Moss, Proc. Natl. Acad. Sci. USA 89:10847-51, 1992.
Schiefiinger, et al., Proc. Natl. Acad. Sci. USA 89:9977-81, 1992.
Merchlinsky, et al., Virology 190:522-6, 1992.
Moss, et al., “Host range restricted, non-replicating vaccinia vires vectors as vaccine candidates.” Advances in Experimentaly Medicine and Biology, 397:7-13, 1996.
Wyatt, et al., (PNAS 101:4590-4595, 2004).
Earl, et al., (Nature 428: 182-185, 2004).
A. Mayr, ZBL Vet B 23, 417-430 (1976).
Blanchard, JT, et al., Journal of General Virology, 79, 1159-1167, 1998.
Bender, et al. Journal of Virology, vol. 70, No. 9, p. 6418-6424, 1996.
Schneider, et al. Nature Medicine, 4, 397-402, 1998.
Sutter, et al. Vaccine 12, 1032-1040, 1994.
Eo, et al., The Journal of Immunology 166: 5473-5479, 2001.
Holzer, et al., Journal of Virology 73: 4536-4542, 1998.
Antione, et al., Virology 244: 365-396, 1998.
Gilbert, et al., Biol. Chem. 380: 299-303, 1999.
Behera, et al., Hum. Gene Ther. 13 (14): 1697-709, 2002.
Belyakov, et al., Proc. Natl. Acad. Sci. 100: 9458-9463, 2003.
Hanke, et al., Journal of Viroogy 73: 7524-7532, 1999.
Danish Search Report; PA 2002 01302/P2/TBS: Jul. 10, 2003.
International Search Report: PCT EP 03/09704: Jan. 30, 2003.
International Preliminary Examination Report: PCT EP03/09704: Oct. 20, 2004.
Danish Search Report: PA 2000 01764/P2/FRE: Oct. 27, 2001.
International Search Report: PCT EP01/13628: May 24, 2002.
International Preliminary Examination Report: PCT/EPO1/13628: Mar. 25, 2003.
In the matter of: Certain Modified Vaccinia Ankara (“MVA”) Viruses and Vaccines and Pharmaceutical Compositions Based Thereon, Investigation No. 337-TA-550,Order No. 28: Denying in Part Complainant's Motion for Summary Determination and Denying in Part Respondent's Motion for Summary Determination, Untied States International Trade Commission, Washington, D.C., Apr. 18, 2006.
In the matter of: Certain Modified Vaccinia Ankara (“MVA”) Viruses and Vaccines and Pharmaceutical Compositions Based Thereon, Investigation No. 337-TA-550,Nucleotide alignment of MVA-Antione vs Acambis 3000 MVA vs MVA-BN, Aug. 31, 2005.
In the matter of: Certain Modified Vaccinia Ankara (“MVA”) Viruses and Vaccines and Pharmaceutical Compositions Based Thereon, Investigation No. 337-TA-550,Respondent's Amended Pre-Hearing Brief, United States International Trade Commission, Washington, D.C., May 8, 2006.
In the matter of: Certain Modified Vaccinia Ankara (“MVA”) Viruses and Vaccines and Pharmaceutical Compositions Based Thereon, Investigation No. 337-TA-550,Respondent's Opposition to Compainant's Motion for Sanctions, United States International Trade Commission, Washington, D.C., Jul. 7, 2006.
In the matter of: Certain Modified Vaccinia Ankara (“MVA”) Viruses and Vaccines and Pharmaceutical Compositions Based Thereon, Investigation No. 337-TA-550,Respondent's Opposition to Compainant's Motion for Summary Determination of Infringement, 10439953.051603 United States International Trade Commission, Washington, D.C.
In the matter of: Certain Modified Vaccinia Ankara (“MVA”) Viruses and Vaccines and Pharmaceutical Compositions Based Thereon, Investigation No. 337-TA-550,Respondent's Rebuttal to Compainant's Proposed Conclusions of Law, United States International Trade Commission, Washinton, D.C., Jun. 14, 2006.
In the matter of: Certain Modified Vaccinia Ankara (“MVA”) Viruses and Vaccines and Pharmaceutical Compositions Based Thereon, Investigation No. 337-TA-550,Compainant Bavarian Nordic's Motion for Sanctions and Memorandum in Support of its Motion, United States International Trade Commission, Washington, D.C., Jun. 21, 2006 (Public Version).
In the matter of: Certain Modified Vaccinia Ankara (“MVA”) Viruses and Vaccines and Pharmaceutical Compositions Based Thereon, Investigation No. 337-TA-550,Memorandum in Oppostion to Respondent's Motion for Summary Determination, United States International Trade Commission, Washington, D.C., Mar. 30, 2006 (Public Version).
In the matter of: Certain Modified Vaccinia Ankara (“MVA”) Viruses and Vaccines and Pharmaceutical Compositions Based Thereon, Investigation No. 337-TA-550,Compainant Bavarian Nordic's Memorandum in Support of
Chaplin Paul
Felder Eva
Heller Karl
Howley Paul
Meisinger Christine
Bavarian Nordic A/S
Blumel Benjamin P
Campell Bruce
Law Office of Salvatore Arrigo
LandOfFree
Modified Vaccinia Ankara virus variant and cultivation method does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modified Vaccinia Ankara virus variant and cultivation method, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modified Vaccinia Ankara virus variant and cultivation method will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4025085